Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
52.4M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
45M
-
Shares change
-
-2.62M
-
Total reported value, excl. options
-
$212M
-
Value change
-
-$12.1M
-
Put/Call ratio
-
0.16
-
Number of buys
-
36
-
Number of sells
-
-48
-
Price
-
$4.72
Significant Holders of 2seventy bio, Inc. - Common Stock (TSVT) as of Q3 2024
128 filings reported holding TSVT - 2seventy bio, Inc. - Common Stock as of Q3 2024.
2seventy bio, Inc. - Common Stock (TSVT) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45M shares
of 52.4M outstanding shares and own 85.89% of the company stock.
Largest 10 shareholders include Kynam Capital Management, LP (5.95M shares), GOLDMAN SACHS GROUP INC (4.22M shares), BlackRock, Inc. (3.87M shares), VANGUARD GROUP INC (3.77M shares), MORGAN STANLEY (2.89M shares), Madison Avenue Partners, LP (2.56M shares), Newtyn Management, LLC (2.54M shares), BAKER BROS. ADVISORS LP (2.5M shares), Casdin Capital, LLC (2M shares), and DEUTSCHE BANK AG\ (1.33M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.